Ryanair Wins German Court Case Against Travel Website eDreams — Update
By Pierre Bertrand
Ryanair said the Berlin Regional Court ruled in its favor against travel website eDreams, marking the second such victory for the airline in recent weeks.
The Berlin court found that eDreams' payment service fee of 3.88 euros ($4.21) was excessive and unlawful. It also ruled that the website's 'flexfare' feature was misleading.
In addition, the court separately granted an injuction in favor of the Irish low-cost airline against the terms and conditions of eDreams Prime.
The ruling comes as part of the airline's longstanding fight against some online travel agencies which it says redirect and overcharge consumers.
It marks the second such outcome in favor of the airline in recent weeks. On July 19, Ryanair won in the Delaware District Court against Booking.com which was found in breach of the U.S. Computer Fraud and Abuse Act.
eDreams wasn't immediately available for comment when approached by Dow Jones Newswires.
Despite such legal wrangling, Ryanair is currently working to strengthen relationships with select websites that make up its list of "approved online travel agencies."
Earlier this month, the company signed its first commercial agreement with Switzerland-listed Lastminute.com to offer the airline's flights to customers for a period of three years.
Last week, Ryanair also struck a similar deal with Expedia Group.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
July 25, 2024 12:18 ET (16:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks